U.S. Markets closed

4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)

CORAL GABLES, FL / ACCESSWIRE / January 24, 2019 / The healthcare stock market has become a hotbed of conversation over the course of the past year or so, with headlines on the industry hitting the media on a consistent basis. Companies in the space have tasked their medical experts and professionals to champion effective solutions to improve the quality of care currently available to consumers. With the constant excitement whirring around the healthcare sector, it stands to reason that companies looking to design and try new approaches to traditional care offerings could create potential opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Lipocine Inc., (LPCN), Microbot Medical Inc., (MBOT), and Capricor Therapeutics Inc., (CAPR) represent four healthcare companies determined to invest in the betterment of healthcare.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that the Company is moving forward with a binding Letter of Intent to a acquire two Metro Vancouver-based pharmacies. The pharmacies were cash flow positive and had combined annual revenue of over $6 million for the recent fiscal year ended May 31, 2018.

In a press release regarding the update, Dr. Essam Hamza, CEO of Premier, said, ''We are very excited about this opportunity to acquire two well-run and profitable pharmacies. As part of our patient-centric model, fill and fulfillment is a major component of our telemedicine app. We are also pleased to have the pharmacies' key management team, with over 20 years' experience managing pharmacies, come on board to continue running the operations. We look forward to working together to improve fulfillment for our rapidly growing patient base. In addition, with one of the pharmacies occupying a space of over 6000 square feet, we have a potential opportunity for a brand-new medical clinic expansion.''

For More Information On Premier Health Group, Click Here

Lipocine Inc (LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a Phase 2 clinical study of their non-alcoholic steatohepatitis treatment.

Following the announcement, Dr. Mahesh Patel, Chairman, President and CEO of Lipocine, commented, ''This IND filing is an important step forward as we pursue further evaluation of LPCN 1144 in biopsy confirmed NASH patients for the treatment of NASH. There is currently no FDA approved product for the treatment of NASH and we believe our well-tolerated oral LPCN 1144 is well positioned to mechanistically address this disease and provide additional unmet benefits.''

For More Information On Lipocine Inc., Click Here

Microbot Medical Inc (MBOT), a medical device company which specializes in the design and development of micro-robotic medical tech, announced earlier this week that they have entered into definitive agreements with institutional investors for the purchase of 250,000 shares of its common stock, at the purchase price per share of $10.00, in a registered direct offering priced at-the-market.

Per the details of the announcement, Microbot currently intends to use the net proceeds from this offering for the continuous development of its SCS device for the treatment of hydrocephalus and NPH; to expand and develop additional applications deriving from its existing IP portfolio, including the potential addition of complementary assets to the CardioSert portfolio either through internal development, in-license or acquisition; and for working capital and other general corporate purposes.

For More Information on Microbot Medical Inc., Click Here

Capricor Therapeutics Inc (CAPR) recently had one of its cell therapy treatments evaluated by Neurology, an international peer-review journal, and the publication released the results of the said trial earlier this week. Per the results, The Phase I/II, randomized, controlled, open-label trial found that CAP-1002 demonstrated improvement in cardiac muscle function and reduction in cardiac scarring that was statistically significant and sustained improvement of skeletal muscle functions in patients with Duchenne muscular dystrophy, a fatal genetic disease with limited treatment options.

Linda Marban, Capricor CEO, commented, ''Capricor's pre-clinical studies and the HOPE-Duchenne trial provide evidence that CAP-1002 can help preserve skeletal and cardiac muscle function in patients in the advanced stages of Duchenne muscular dystrophy. Most importantly, we have shown that there is an opportunity for stabilization or even improvement of disease in patients with later stage Duchenne muscular dystrophy, which represents a large proportion of those living with the disease.''

For More Information On Capricor Therapeutics Inc., Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018-4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/24/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.

CONTACT:

news@stockprice.com

SOURCE: Stock Price